May 29, 2013, 07.50 PM | Source: CNBC-TV18
Ashu Madan, president of core client group at Religare Securities advised buying Dishman Pharma at current levels. In short-term, the stock can go up by 10-15 percent, feels Madan.
Ashu Madan (more)
COO, Religare Capital | Capital Expertise: Equity - Technical ,Equity - Fundamental
“In short-term one might get 10-15 percent return soon. So in any case if somebody can hold it for longer it would be better, but the current price at which it is hovering around is a good price to buy,” Madan said.
The company, which today announced plans to sell 5
Dishman Pharmaceuticals and Chemicals Ltd has info
Dishman Pharmaceuticals has approved the issue and
On CNBC-TV18's show Super Six, market gurus Vishal
Union Bank of India | ONGC | BHEL | Akzo Noble | F
Bull's Eye, CNBC-TV18's popular game show, where m
Buy DLF, says Sudarshan Sukhani of s2analytics.com
Sudarshan Sukhani of s2analytics.com shares his vi